Save up -80% on Asfotase Alfa

Note: this is a drug discount program, not an insurance plan.

RX BIN: 015558
RX PCN: HT
Group ID: DDN6600
Card Holder ID: DDN6600

Pharmacists and Patients support.

2018 Price of Asfotase Alfa

$

* price without discount in nearest pharmacy. Price may vary.

Claim your free Asfotase Alfa discount card

We offer free Asfotase Alfa coupons and discounts that may help you save up to 80% off the retail price in your local pharmacy. Just print your coupon! It’s ready to use and never expire. Present your discount card in most local pharmacies to get a discount on Asfotase Alfa every time. What are you waiting for? Claim your prescription drug card now!

Get your Prescription
It’s safe and free
Buy drugs in pharmacy
Save money each time

Asfotase Alfa volume of distribution

About RX24Drugs

Discount Cards 16,000+

Clients Benefit 29%

Total savings $4,735,080

What is Asfotase Alfa

Asfotase Alfa is a first-in-class bone-targeted enzyme replacement therapy designed to address the underlying cause of hypophosphatasia (HPP) deficient alkaline phosphatase (ALP). Hypophosphatasia is almost always fatal when severe skeletal disease is obvious at birth. By replacing deficient ALP, treatment with Asfotase Alfa aims to improve the elevated enzyme substrate levels and improve the body’s ability to mineralize bone, thereby preventing serious skeletal and systemic patient morbidity and premature death. Asfotase alfa was first approved by Pharmaceuticals and Medicals Devices Agency of Japan (PMDA) on July 3, 2015, then approved by the European Medicine Agency (EMA) on August 28, 2015, and was approved by the U.S. Food and Drug Administration (FDA) on October 23, 2015. Asfotase Alfa is marketed under the brand name Strensiq by Alexion Pharmaceuticals, Inc. The annual average price of Asfotase Alfa treatment is $285,000.

Asfotase Alfa mechanism of action

HPP is caused by a deficiency in TNSALP (tissue non-specific alkaline phosphatase) enzyme activity, which leads to elevations in several TNSALP substrates, including inorganic pyrophosphate (PPi). Elevated extracellular levels of PPi block hydroxyapatite crystal growth which inhibits bone mineralization and causes an accumulation of unmineralized bone matrix which manifests as rickets and bone deformation in infants and children and as osteomalacia (softening of bones) once growth plates close, along with muscle weakness. Replacement of the TNSALP enzyme upon Asfotase alfa treatment reduces the enzyme substrate levels.

Dosage forms of Asfotase Alfa

FormRouteStrength
Solutionsubcutaneous100 mg
Solutionsubcutaneous18 mg/.45mL
Solutionsubcutaneous28 mg/.7mL
Prescription Generics

false

International Brands

Strensiq

Synonyms

Asfotase alpha

Manufacturers

Alexion Pharma Ghbh

CAS number

1174277-80-5

UNII

Z633861EIM

State

liquid

Affected organisms

Humans and other mammals

Indication of Asfotase Alfa

Indicated for the treatment of patients with perinatal/infantile and juvenile onset hypophosphatasia (HPP).

Toxicity of Asfotase Alfa

There are no available human data on Asfotase Alfa use in pregnant women to inform a drug associated risk. In animal reproduction studies, Asfotase Alfa administered intravenously to pregnant rats and rabbits during the period of organogenesis showed no evidence of fetotoxicity, embryolethality or teratogenicity at doses causing plasma exposures up to 21 and 24 times, respectively, the exposure at the recommended human dose.

RX24 Drugs Disclaimer: before buying a Asfotase Alfa on prescription, consult your healthcare provider. Content on this page is provided for informational purposes only. Any use of this information is at your own risk.

Get lower price on Asfotase Alfa now!